Health and Healthcare
Cramer Speculates on Dialysis Drug (AMAG, XCR)
Published:
Last Updated:
On tonight’s MAD MONEY on CNBC, Jim Cramer said he had a speculative biotech stock. His pick in the sector is AMAG Pharmaceuticals, Inc. (AMAG) because of its soon to be approved ferumoxytol, a newer and better intravenous iron treatment for kidney disease patients on dialysis. Cramer thinks there are many reasons to like this one:
We recently covered a speculative portable dialysis device maker (in prototype and development stage) on our "10 Stocks Under $10" called Xcorporeal, Inc. (AMEX: XCR) which has risen in the last two weeks since being included. We have also reviewed some of the lower-tier dialysis names for this as well.
We would note that this AMAG traded at $56.00 after an upgrade just in early February and shares closed under $40.00 Friday.
Jon C. Ogg
March 28, 2008
Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at [email protected]; he does not own securities in the companies he covers.
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.